Navigation Links
PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Date:7/16/2008

- Expanded Collaboration Supports Pivotal Phase 2b Clinical Trials of First Potential Therapy to Address an Underlying Cause of Cystic Fibrosis -

SOUTH PLAINFIELD, N.J. and BETHESDA, Md., July 16 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced the expansion of an existing collaboration to support development of PTC124, the PTC's new investigational oral drug for the treatment of cystic fibrosis (CF) caused by nonsense mutations. PTC will receive up to $25 million from CFFT in support of key Phase 2b clinical trials for PTC124 in CF.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are pleased to expand our collaboration with PTC Therapeutics on the development of the therapy PTC124," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "The encouraging data from the Phase 2a studies indicate that PTC may become a very important drug for the treatment of CF in the 10 percent of patients who carry nonsense mutations. These exciting results lead us to believe PTC124 has the potential to be one of the first oral drugs on the market to address the basic defect in cystic fibrosis."

"We are honored both to receive this award and to continue our productive collaboration with the Foundation," stated Stuart W. Peltz, Ph.D., president and chief executive officer of PTC Therapeutics. "The significant progress that we have made with PTC124 is a result of our unique drug discovery approach as well as the extraordinary support that we have received from the physician, patient, advocacy and regulatory communities. We look forward to initiating registration-directed studies of PTC124 for nonsense-mutation- mediated CF within the next few months."

In June 2008, PTC announced encouraging new
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Board Changes
5. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, ... medical device company developing its Symphony® CGM System ... today announced that Robert F. Doman , ... will present at "TEN", Noble Financial Capital Markets, ... Doman will make a corporate presentation to prospective ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... S.r.l. a full service and,leading clinical research organization (CRO), ... Research S.r.l., a CRO focused on Phase I to,Phase ... http://www.newscom.com/cgi-bin/prnh/20080122/335477 ) , ... and have legal and,operating offices in Milan, Italy. The ...
... DIO Rats Highlighted -PLYMOUTH MEETING, Pa., Jan. 22 ... GENR ) today announced a poster presentation ... drug candidate for the treatment of type 2 ... - Novel Aspects of the Regulation of Body ...
Cached Medicine Technology:Phidea Srl and Marvin Research Srl Announce Completion of Merger 2Phidea Srl and Marvin Research Srl Announce Completion of Merger 3Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 2Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... and Soothes Young Throats Now Available,Across the Northern ... cough and cold season,rapidly approaches, Integrated Beverage Group, ... products has launched its newest product,in Canada -- ... a perfect choice for parents who wish to,choose ...
... Company to Serve About 50,000 People Beginning February 1, ... AMERIGROUP,Corporation (NYSE: AGP ) announced today that the ... authorizing the Company,s Nevada subsidiary to,enter that State,s Medicaid ... 2009., The Nevada State Board of Examiners has ...
... lead to new treatments, researchers say , , WEDNESDAY, Nov. ... cells exhausted from fighting HIV infection has been discovered ... a molecule called Tim-3 is present at high levels ... HIV, the virus that causes AIDS. Blocking the activity ...
... Expertise to ... ... the,election of Jay Parsons to the company,s board of directors effective,immediately., ... programs and the development of customized incentive programs,that help consumers make ...
... likely to skip medicines, compared to whites , , WEDNESDAY, ... that included encouragement and occasional gifts improved medication adherence ... Americans with high blood pressure, a new study found. ... be nearly twice as likely to not take their ...
... That Demonstrate Best Strategic Use of Mergers ... ... Deal,( http://www.thedeal.com ) magazine has named Abbott,( http://www.abbott.com )as the healthcare ... honored Abbott for the,most effective strategic use of acquisitions and divestitures., ...
Cached Medicine News:Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 2Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 4Health News:Way to Rescue Tired Immune Cells Fighting HIV Found 2Health News:MedVantx(R) Names Newest Board Member 2Health News:Education Program Spurs Blacks to Take Blood Pressure Meds 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 3
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
... automated genetic analysis system. This system automatically ... linear polyacrylamide (LPA) gel, denatures and loads ... analyzes the data. Software tools let you ... automated data assessment. All to ensure unprecedented ...
ELISA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum...
Medicine Products: